SCHEMBL11254

SCHEMBL11254

Cc1nc(N)nc(Cl)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14020978 0.82
Ammonia Solution, Strong SCHEMBL19469409 0.82 HSP90AB1 (0.55)
SCHEMBL94294 0.78
SCHEMBL79810 0.78
SCHEMBL802854 0.78
SCHEMBL197055 0.78
SCHEMBL664729 0.78
SCHEMBL36733 0.78
SCHEMBL11193332 0.72 HSP90AB1 (0.46)
Methoxymethane SCHEMBL3858154 0.71 HSP90AB1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594308-A1 N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF Vividion Therapeutics, Inc. (US) 2025-08-06 EP disclosed
WO-2025081019-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2025-04-17 WO disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed
WO-2024137984-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
WO-2024137984-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
EP-1087948-A1 2,4-DIAMINO-1,3,5-TRIAZINE, METHOD FOR THE PRODUCTION AND USE OF THE SAME AS HERBICIDES AND PLANT GROWTH REGULATORS Aventis CropScience GmbH (DE) 2001-04-04 EP disclosed
WO-1999065882-A1 2,4-DIAMINO-1,3,5-TRIAZINE, METHOD FOR THE PRODUCTION AND USE OF THE SAME AS HERBICIDES AND PLANT GROWTH REGULATORS AVENTIS CROPSCIENCE GMBH (DE) 1999-12-23 WO disclosed
EP-0463998-B1 Immunological detection of triasulfuron CIBA GEIGY AG (CH) 1997-01-15 EP disclosed
US-5574037-A MODULATED BY SINO-ATRIAL NODE, ANTIISCHEMIC AGENT IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1996-11-12 US disclosed
US-5563074-A ANTIBODY SPECIFIC TO SULFONYLUREA HERBICIDE CIBA-GEIGY CORPORATION (US) 1996-10-08 US disclosed
EP-0431856-B1 Heterocyclic compounds ZENECA LTD (GB) 1995-07-12 EP disclosed
US-5359135-A Detection in soil, water, air by preferential affinity to monoclonal antibodies CIBA-GEIGY CORPORATION (US) 1994-10-25 US disclosed
US-5332737-A Cardiovascular disorders IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-07-26 US disclosed
EP-0463998-A2 Immunological detection of triasulfuron CIBA-GEIGY AG (CH) 1992-01-02 EP disclosed
EP-0431856-A2 Heterocyclic compounds ZENECA LIMITED (GB) 1991-06-12 EP disclosed